Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro.

Abstract

Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in mammalian cells and virus replication in a hamster model. Furthermore, we demonstrate that plasma concentrations up to 50-fold higher than the protein binding adjusted IC90 value are achievable for 24 h following a single oral dose. These data support the potential clinical utility of probenecid to control SARS-CoV-2 infection in humans.

• Authors: Jackelyn Murray, Robert J Hogan, David E Martin, Kathy Blahunka, Fred D Sancilio, Rajiv Balyan, Mark Lovern, Richard Still, Ralph A Tripp
• Journal: Scientific reports (Sci Rep) Vol. 11 Issue 1 Pg. 18085 (09 10 2021) ISSN: 2045-2322 [Electronic] England
• PMID: 34508172 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021. The Author(s).

Chemical References

• Antiviral Agents
• Probenecid

Topics

• Animals
• Antiviral Agents (pharmacology)
• Chlorocebus aethiops
• Epithelial Cells (drug effects, virology)
• Humans
• Lung (drug effects, virology)
• Probenecid (pharmacology)
• SARS-CoV-2 (physiology)
• Vero Cells
• Virus Replication (drug effects)